These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 12053315)

  • 1. Patent foramen ovale closure in patients with transient ischemia attack/stroke.
    Sievert H; Horvath K; Zadan E; Krumsdorf U; Fach A; Merle H; Scherer D; Schräder R; Spies H; Nowak B; Lissmann-Jensen H
    J Interv Cardiol; 2001 Apr; 14(2):261-6. PubMed ID: 12053315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale.
    Hornung M; Bertog SC; Franke J; Id D; Taaffe M; Wunderlich N; Vaskelyte L; Hofmann I; Sievert H
    Eur Heart J; 2013 Nov; 34(43):3362-9. PubMed ID: 23842846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interventional occlusion of foramen ovale and atrial septal defects after paradoxical embolism incidents].
    Beitzke A; Schuchlenz H; Beitzke M; Gamillscheg A; Stein HI; Zartner P
    Z Kardiol; 2002 Sep; 91(9):693-700. PubMed ID: 12448068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catheter closure of atrial septal defects and patent foramen ovale in patients with an atrial septal aneurysm using different devices.
    Krumsdorf U; Keppeler P; Horvath K; Zadan E; Schrader R; Sievert H
    J Interv Cardiol; 2001 Feb; 14(1):49-55. PubMed ID: 12053327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcatheter closure of patent foramen ovale associated with paradoxical embolism using the amplatzer PFO occluder: initial and intermediate-term results of the U.S. multicenter clinical trial.
    Hong TE; Thaler D; Brorson J; Heitschmidt M; Hijazi ZM;
    Catheter Cardiovasc Interv; 2003 Dec; 60(4):524-8. PubMed ID: 14624434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism.
    Khositseth A; Cabalka AK; Sweeney JP; Fortuin FD; Reeder GS; Connolly HM; Hagler DJ
    Mayo Clin Proc; 2004 Jan; 79(1):35-41. PubMed ID: 14708946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement.
    Hung J; Landzberg MJ; Jenkins KJ; King ME; Lock JE; Palacios IF; Lang P
    J Am Coll Cardiol; 2000 Apr; 35(5):1311-6. PubMed ID: 10758974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism.
    Chatterjee T; Petzsch M; Ince H; Rehders TC; Körber T; Weber F; Schneider H; Auf der Maur C; Nienaber CA
    J Interv Cardiol; 2005 Jun; 18(3):173-9. PubMed ID: 15966921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous closure of a patent foramen ovale: single-centre experience using different types of devices and mid-term outcome.
    Post MC; Van Deyk K; Budts W
    Acta Cardiol; 2005 Oct; 60(5):515-9. PubMed ID: 16261783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcatheter closure of patent foramen ovale in patients with cerebral ischemia.
    Braun MU; Fassbender D; Schoen SP; Haass M; Schraeder R; Scholtz W; Strasser RH
    J Am Coll Cardiol; 2002 Jun; 39(12):2019-25. PubMed ID: 12084603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events.
    Windecker S; Wahl A; Chatterjee T; Garachemani A; Eberli FR; Seiler C; Meier B
    Circulation; 2000 Feb; 101(8):893-8. PubMed ID: 10694529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-Market Clinical Follow-Up With the Patent Foramen Ovale Closure Device IrisFIT (Lifetech) in Patients With Stroke, Transient Ischemic Attack, or Other Thromboembolic Events.
    Sievert K; Yu J; Bertog S; Hornung M; von Bardeleben RS; Gafoor S; Reinartz M; Matic P; Hofmann I; Grunwald I; Schnelle N; Sievert H
    Cardiovasc Revasc Med; 2021 Sep; 30():72-75. PubMed ID: 33097460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous closure of patent foramen ovale in symptomatic patients.
    Wahl A; Windecker S; Eberli FR; Seiler C; Meier B
    J Interv Cardiol; 2001 Apr; 14(2):203-9. PubMed ID: 12053306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
    Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcatheter closure of patent foramen ovale in patients with cryptogenic stroke.
    Butera G; Bini MR; Chessa M; Bedogni F; Onofri M; Carminati M
    Ital Heart J; 2001 Feb; 2(2):115-8. PubMed ID: 11256538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems.
    Braun M; Gliech V; Boscheri A; Schoen S; Gahn G; Reichmann H; Haass M; Schraeder R; Strasser RH
    Eur Heart J; 2004 Mar; 25(5):424-30. PubMed ID: 15033255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer versus CardioSEAL-STARflex versus Helex occluder).
    Taaffe M; Fischer E; Baranowski A; Majunke N; Heinisch C; Leetz M; Hein R; Bayard Y; Büscheck F; Reschke M; Hoffmann I; Wunderlich N; Wilson N; Sievert H
    Am J Cardiol; 2008 May; 101(9):1353-8. PubMed ID: 18435971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke.
    Thanopoulos BV; Dardas PD; Karanasios E; Mezilis N
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):741-6. PubMed ID: 17039525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and follow-up results after implantation of the Amplatzer®-occluder device.
    Fischer D; Haentjes J; Klein G; Schieffer B; Drexler H; Meyer GP; Schaefer A
    J Interv Cardiol; 2011 Feb; 24(1):85-91. PubMed ID: 20735710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.